English | Español

Novartis
Amanda Rupp | Aug 31, 2016

Sandoz's Erelzi gains FDA approval for multiple inflammatory diseases
Jamie Barrand | Feb 20, 2016

Novartis' new AML therapy granted FDA Breakthrough Designation
Jamie Barrand | Feb 20, 2016

Alcon, Transcend Medical partner on glaucoma therapy project
Jamie Barrand | Feb 13, 2016

Sandoz acquires infliximab inhibitor treatment from Pfizer
Kasey Schefflin- Emrich | Jan 28, 2016

FDA approves Cosentyx as treatment for two inflammatory conditions

Trending
Patient Daily | Aug 18, 2025

Medfluence Advisors’ Greg Caesar to open ASCENT 2025 with keynote on digital practice growth
+ Pharmaceuticals
Patient Daily | Aug 18, 2025

Patients Come First spokesperson on 340B rebate model: ‘This rebate model provides the oversight that 340B has needed for decades’
Patient Daily | Aug 21, 2025

SoCal Breathe Free doctor on balloon sinuplasty: ‘The procedure itself is pretty quick and effectiveness is pretty high’
+ Pharmaceuticals
Patient Daily | Aug 21, 2025

PhRMA director of public affairs on 340B rebate model: "Positive first step toward addressing hospital abuse of the 340B program